source
- Full-Life Technologies secures $150M Series D financingFull-Life Technologies announced it has raised $150 million in a Series D financing round, comprising $110 million in the main tranche and an additional $40 million. The capital is intended to adv…
- Relay Therapeutics' zovegalisib shows 60% response in mid‑stage trial for rare vascular anomaliesRelay Therapeutics reported early data from a phase 2 trial of its experimental drug zovegalisib in patients with vascular anomalies, a group of rare disorders characterized by abnormal blood vesse…